Key Highlights
- To understand why this particular group of companies matters, it helps to step back and consider the shape of UK-listed healthcare in 2026. The sector is anchored at the top by two very large constituents of the FTSE 100 that pull in opposite directions stylistically.
- Hikma Pharmaceuticals PLC (LSE:HIK): The most recent substantive disclosure was Hikma’s first-half results for the six months to 30 June 2026, reported on 6 August 2026.
- ConvaTec Group PLC (LSE:CTEC): ConvaTec’s half-year results for the six months to 30 June 2026 were reported on 4 August 2026.
- Shield Therapeutics plc (LSE:STX): Shield issued a Q2/H1 trading update on 30 July 2026 and full interim results on 20 August 2026.
- Haleon plc (LSE:HLN): Haleon reported its 2026 half-year results on 30 July 2026.
- AstraZeneca PLC (LSE:AZN): The standout recent event was a regulatory approval.
- Venture Life Group plc (LSE:VLG): Venture Life changed its financial year-end to 31 May, from 31 December, creating a 17-month transition period ended 31 May 2026.
- Diaceutics PLC (LSE:DXRX): Diaceutics issued an H1 2026 trading update on 29 July 2026.
Healthcare has long occupied an outsized place in the thinking of UK Equity investors, and for good reason. It is one of the few sectors where the London market can genuinely claim global leadership, where defensive cash generation sits alongside the prospect of genuine scientific breakthrough, and where a single regulatory decision can move billions of pounds of value in a morning. As the autumn of 2026 gets under way, the sector spans an unusually wide spectrum, from a trillion-pound-scale oncology Franchise down to micro-cap commercial-stage specialists whose fortunes turn on a handful of contracts or a thin cash runway.
This article looks at seven London-listed healthcare names that, for very different reasons, are worth following through the remainder of September 2026: Hikma Pharmaceuticals (LSE:HIK), ConvaTec Group (LSE:CTEC), Shield Therapeutics (LSE:STX), Haleon (LSE:HLN), AstraZeneca (LSE:AZN), Venture Life Group (LSE:VLG) and Diaceutics (LSE:DXRX).
A point worth stressing at the outset is that the “FTSE” label in the headline is deliberately broad. These seven companies do not all sit in the same index, or even on the same market. AstraZeneca, Haleon and ConvaTec are FTSE 100 constituents on the London Main Market. Hikma, once a FTSE 100 member, was relegated to the FTSE 250 at the March 2026 index review. The remaining three — Shield Therapeutics, Venture Life Group and Diaceutics — trade on AIM, London’s growth market, and feature in the FTSE AIM All-Share. So the line-up straddles the Main Market and AIM, Blue-Chip Liquidity and small-cap volatility, and everything in between. That breadth is part of the point: UK healthcare is not a monolith but a layered ecosystem of innovator pharma, generics, medical technology, consumer self-care and the data and diagnostics businesses that increasingly knit them together.
What follows is a company-by-company survey grounded in the most recent disclosures available as of early September 2026 — chiefly the half-year and interim results that landed across July and August, plus a handful of regulatory and corporate milestones. The aim is to set out the facts, the near-term catalysts each company has flagged, and the specific risks that attach to each, before drawing the threads together. Nothing here is Investment advice, and no view is offered on whether any of these shares will rise or fall. Markets in healthcare are driven by clinical data, pricing policy and execution, all of which can surprise in either direction. The intention is simply to help readers understand what these seven businesses do, where they stand, and what they themselves have told the market to watch.
UK Healthcare Market Backdrop
To understand why this particular group of companies matters, it helps to step back and consider the shape of UK-listed healthcare in 2026. The sector is anchored at the top by two very large constituents of the FTSE 100 that pull in opposite directions stylistically. AstraZeneca is the outright heavyweight, the single largest company in the index by market value, an innovator biopharma Business whose growth is powered by patent-protected medicines and a deep clinical pipeline. Haleon, by contrast, is the world’s largest pure-play consumer-health company, spun out of GSK in 2022, whose appeal rests on the steady, defensive Economics of everyday self-care brands rather than on the binary outcomes of drug trials. Between them they illustrate the two poles of the sector: the high-risk, high-reward science of new medicines and the slower-burning compounding of consumer staples with a health twist.
Around those anchors sits a middle tier of specialists. ConvaTec, also in the FTSE 100, is a medical-technology business built on chronic-care consumables — wound care, ostomy, continence and infusion products — where the economics look more like recurring consumer Demand than episodic drug sales, but with the regulatory and reimbursement overlay of medtech. Hikma occupies the generics and specialty niche, a maker of sterile injectables and oral generics in the United States alongside a leading branded business across the Middle East and North Africa. Generics sit at the opposite end of the pricing spectrum from innovator pharma: the challenge is not Patent protection but cost, scale, Supply reliability and the relentless price erosion that competition brings.
Then there is the AIM cohort. Shield Therapeutics is a commercial-stage specialty pharma company built around a single oral iron-deficiency product. Venture Life Group is a consumer self-care business assembling a portfolio of owned “Power Brands”. Diaceutics is something different again — a precision-medicine enablement business that sells data, analytics and engagement technology to pharmaceutical companies trying to get the right diagnostic tests to the right patients. These smaller names carry the characteristic features of AIM: thinner liquidity, sharper share-price swings around results, and a closer dependence on a small number of products, partners or customers.
Several themes cut across the whole sector as autumn 2026 begins. The first is the persistent tension between consumer health, innovator pharma and generics as business models. Consumer-health names such as Haleon and Venture Life trade on Brand equity, pricing power and repeat purchase, and their risks are about demand softness, private-label competition and retailer behaviour. Innovator pharma lives and dies by the pipeline and by patent cliffs. Generics compete on price and supply. Understanding which bucket a company sits in is the first step to understanding its risk profile.
The second theme is the United States. For almost every company here, the US is the most important single market, which makes US healthcare policy a recurring source of uncertainty. Drug-pricing reform, the ongoing implementation of Medicare negotiation provisions, Medicaid prior-authorisation practices at state level, and reimbursement decisions for specific products all bear directly on revenue. On top of that sits the prospect of tariffs on pharmaceutical imports, a risk that several of these companies explicitly flag. A UK-listed manufacturer selling into the US faces both the policy risk on price and the trade risk on cost, and the two can compound.
The third theme is oncology momentum. Cancer medicine remains the most commercially and scientifically dynamic corner of the sector, and AstraZeneca’s oncology franchise in particular has been a reliable engine of growth, accounting for a large and rising share of its product sales. The steady flow of regulatory decisions, trial readouts and approvals in oncology is one of the defining rhythms of the UK healthcare calendar, and it continues through 2026.
Finally, there is the quieter but growing role of data and diagnostics. Precision medicine — matching treatments to patients on the basis of genetic or biomarker testing — depends on the infrastructure of diagnostic testing and the data that surrounds it. That is the space Diaceutics occupies, and it is a reminder that the sector’s value chain now extends well beyond the companies that make pills and devices.
Against that backdrop, the seven companies below offer a cross-section of UK healthcare in 2026: two mega-caps, a MedTech major, a generics specialist, and three AIM businesses spanning pharma, consumer health and healthtech data.
Hikma Pharmaceuticals PLC (LSE:HIK)
Company overview
Hikma Pharmaceuticals is a specialty and generics pharmaceutical company with three core divisions. Its Injectables business supplies generic sterile injectable medicines across the United States, Europe and the MENA region. Its Branded division is a leader in the Middle East and North Africa, where Hikma has deep roots. And its Hikma Rx / Generics arm supplies oral and other generic medicines, principally in the United States. Following the March 2026 FTSE index review, Hikma was relegated from the FTSE 100 to the FTSE 250, though it remains a premium-listed company on the Main Market. As of around 10 September 2026 its Market Capitalisation stood at roughly £3.18bn, on approximately 207m shares, with the share price near 1,535p against a 52-week range of 1,187p to 1,865p. The shares had sold off earlier in 2026 on a softer medium-term outlook for the Injectables business.
Latest September 2026 developments
The most recent substantive disclosure was Hikma’s first-half results for the six months to 30 June 2026, reported on 6 August 2026. Group Revenue came in at $1,728m, up 4% (up 3% at constant currency). The divisional picture was uneven: Branded revenue grew 15% to $502m, Injectables was broadly flat at $685m, and Hikma Rx was also flat at $520m. Reported operating profit rose 30% to $336m, while core operating profit increased 9% to $405m and core EBITDA rose 8% to $463m. Reported Basic Earnings Per Share fell 5% to 103 cents, but core basic EPS rose 5% to 128 cents. The Interim Dividend was lifted 6% to 38 cents. The company had completed $227m of its $250m 2026 buyback, and Operating Cash Flow rose 33% to $214m. Net Debt to core EBITDA stood at 1.9x, up from 1.6x at the end of 2025. Hikma reiterated its full-year 2026 guidance of revenue growth of 2–4% at constant currency and core operating profit of $720–770m. Separately, Tobias Hestler was appointed a non-executive director with effect from 7 August 2026.
Major 2026 developments
Earlier in the year, on 26 February 2026, Hikma had reported its 2025 full-year results. Group revenue rose 7% (6% at constant currency) to $3,349m. Reported operating profit fell 11% to $542m, while core operating profit rose 3% to $741m and core EPS rose 2% to 228 cents. The total dividend for the year was increased 5% to 84 cents, and the company announced the $250m buyback for 2026. Alongside the results came a notable governance change: Said Darwazah was to relinquish his Executive Chairman duties to focus solely on the chief executive role. The subsequent relegation to the FTSE 250 at the March review followed the share-price weakness tied to the Injectables outlook.
Products, pipeline and technology
Hikma’s value rests less on a single blockbuster than on breadth and Manufacturing capability. The Injectables division depends on complex sterile manufacturing, an area with high barriers to entry, while the pipeline of biosimilar and complex-injectable launches is a key source of future growth. The Branded business leans on Hikma’s entrenched commercial position across MENA, and the Generics arm competes in the crowded US oral market.
Financial position
The Balance Sheet carries moderate leverage, with net debt to core EBITDA at 1.9x at the half year, up from 1.6x at the end of 2025 partly reflecting the buyback. Cash generation improved markedly in the first half, and the dividend continues to rise. The reiterated full-year guidance suggests management remains comfortable with the trajectory despite the flat Injectables line.
What investors may be watching
Near-term attention is likely to centre on any sign of recovery and Margin improvement in Injectables, the completion of the 2026 buyback, and the cadence of biosimilar and complex-injectable launches. The next scheduled major financial update is the full-year 2026 results, due in February 2027.
Key risks
Hikma faces pricing and competitive pressure in US generic injectables, where price erosion is a structural feature of the market. Injectables volumes and supply reliability are a perennial concern in sterile manufacturing. The MENA franchise carries geopolitical and foreign-exchange exposure. The company also flags the potential for US pharmaceutical tariffs, and its leverage, while moderate, has edged up.
ConvaTec Group PLC (LSE:CTEC)
Company overview
ConvaTec is a medical-technology company focused on chronic-care consumables, and a constituent of the FTSE 100. It operates four franchises: Advanced Wound Care, Ostomy Care, Continence Care and Infusion Care. It also owns InnovaMatrix, a US placental-derived wound biomaterial. As of around 10 September 2026 the market capitalisation was roughly £4.21bn, on about 1.93bn shares, with the price near 217.8p against a 52-week range of 193.0p to 259.2p, the high having been reached on 26 February 2026.
Latest September 2026 developments
ConvaTec’s half-year results for the six months to 30 June 2026 were reported on 4 August 2026. Organic revenue growth, excluding InnovaMatrix, was 5.0%, while reported revenue rose 4.4%. By franchise, Advanced Wound Care contributed $356m, Ostomy $353m (up 4.3% organically), Continence $277m (up 5.9%) and Infusion $246m (up 7.4%). The adjusted Operating Margin was 21.2% and adjusted operating profit was $262m. Reported operating profit, however, fell 36% to $115m, depressed by a $69m non-cash InnovaMatrix Impairment following an approximately 85% cut to the product’s US reimbursement price, together with Amortisation of intangibles related to a prior BMS transaction. Adjusted diluted EPS rose 6.3% to 8.5 cents, while reported diluted EPS was 2.7 cents. Net debt stood at $1,534m, or 2.3x adjusted EBITDA. The interim dividend was raised 15% to 2.166 cents, and a new $200m buyback was announced, to complete by the end of 2026. Full-year 2026 guidance was narrowed to organic revenue growth of 5.5–6.5%, an adjusted operating margin of at least 23.0%, and double-digit adjusted EPS growth, with second-half growth of 6–8%.
Major 2026 developments
The 2025 full-year results, reported in late February 2026, showed reported revenue up 6.5% and organic growth of 6.4% excluding InnovaMatrix, with an adjusted operating margin of 22.3% and adjusted diluted EPS up 16% to 17.6 cents. Net debt was $1,330m, or 2.0x. The total dividend rose 13% to 7.244 cents, and $300m of Buybacks were completed during the year. Management also upgraded its medium-term targets, setting out from 2027 an ambition of organic revenue growth of 6–8% and an adjusted operating margin of 24–26%.
Products and commercial strategy
ConvaTec’s model is built on recurring demand for consumable chronic-care products, which gives it a more predictable revenue base than episodic medtech. The four franchises each address large, ageing patient populations. InnovaMatrix, however, has become a source of volatility: the sharp US reimbursement price cut forced the non-cash impairment and underscores the company’s exposure to US healthcare policy.
Financial position
Leverage ticked up to 2.3x adjusted EBITDA at the half year, from 2.0x at the end of 2025. The wide gap between adjusted and reported earnings — driven by the impairment and amortisation — is a feature investors need to read carefully, as the headline reported figures understate the underlying cash profitability the company emphasises.
What investors may be watching
Key items include whether ConvaTec delivers the accelerated second-half revenue growth and the at-least-23% margin it has guided to, the progress of new-product launches, resolution of the InnovaMatrix reimbursement situation, and execution towards the upgraded 2027 medium-term targets. Full-year 2026 results are due in February 2027.
Key risks
The most acute company-specific risk is continued US reimbursement pressure on InnovaMatrix. Beyond that, ConvaTec flags the potential for US tariffs, foreign-exchange exposure, intense medtech competition from the likes of Coloplast, Hollister, B. Braun and Medtronic, its leverage, and the large gap between reported and adjusted earnings that can cloud the headline picture.
Shield Therapeutics plc (LSE:STX)
Company overview
Shield Therapeutics is a commercial-stage specialty pharmaceutical company focused on iron-deficiency therapeutics, trading on AIM and featuring in the FTSE AIM All-Share. Its business is built around ACCRUFeR, marketed as Feraccru outside the US, an oral therapy based on ferric maltol for iron deficiency and iron-deficiency anaemia. Shield self-commercialises ACCRUFeR in the United States and relies on partners elsewhere: Norgine in Europe, ASK Pharma in China, and MEDLEAP/Vital-NET in Japan. As of around 10 September 2026 the market capitalisation was roughly £52.4m, on about 1.07bn shares, with the price near 4.9p. The 52-week range ran from 3.70p (reached on 4 August 2026) to 12.35p (4 December 2025), and the shares fell around 22% around the H1 2026 results.
Latest September 2026 developments
Shield issued a Q2/H1 trading update on 30 July 2026 and full interim results on 20 August 2026. Total first-half revenue was $30.4m, up around 42% year on year from $21.5m, driven by a $7.9m development milestone from ASK in China plus higher partner royalties. ACCRUFeR US net sales rose 5% to $20.1m, while ex-US milestone and Royalty income jumped to $10.3m from $2.2m. Gross Profit was $18.1m, and the company recorded an operating profit of $0.2m, against a $5.8m loss in the first half of 2025. The net loss narrowed sharply to $2.3m from $9.5m. Cash stood at $8.3m at 30 June 2026, down from around $11.6m at the end of 2025, with long-term debt of $24.9m owed to Runway Growth Capital and maturing in September 2028. US prescriptions rose around 21% to roughly 102,000, but the net price per unit fell to about $208 from $231, reflecting New York Medicaid prior-authorisation headwinds. Management reiterated that the company is on track for operating profitability in 2026. Michael Jensen was appointed chief financial officer with effect from 1 September 2026.
Major 2026 developments
The year brought a series of paediatric label expansions for ferric maltol: US approval for ages 10 and over on 1 April 2026, EU approval for ages 12 and over in May 2026, and UK MHRA approval on 2 July 2026. In Japan, the first patient was enrolled in a Phase II trial of ferric maltol in pulmonary arterial hypertension — an investigational use that is not approved. Audited full-year 2025 results were published on 9 April 2026.
Products, pipeline and technology
Shield is effectively a single-product company, with ACCRUFeR/Feraccru at its core. The paediatric expansions broaden the addressable population, and the ex-US partnerships provide milestone and royalty income that materially boosted first-half revenue. The Japanese PAH programme is a genuinely new avenue, but it is at an early, investigational Phase II stage and should not be read as anything more.
Financial position
The move to a small operating profit and a much-reduced net loss is a meaningful step, but the balance sheet remains tight. Cash of $8.3m against $24.9m of debt maturing in September 2028 leaves limited headroom, making the path to sustained profitability and the inflow of further partner milestones important to the company’s financial stability.
What investors may be watching
Attention is likely to focus on whether Shield delivers full-year operating profitability in 2026, the timing and scale of additional China, Japan and Europe milestone and royalty inflows, progress of the Japan PAH Phase II programme, and the trajectory of US prescriptions alongside any stabilisation in net price.
Key risks
Shield’s risks are concentrated: a thin cash runway set against the 2028 debt maturity, dependence on a single product, the erosion of US net price from Medicaid prior-authorisation requirements, reliance on partners for the ex-US upside, the limited liquidity typical of AIM, and the early-stage nature of the PAH programme.
Haleon plc (LSE:HLN)
Company overview
Haleon is the world’s largest pure-play consumer-health company, created by the 2022 demerger from GSK. It is listed on the London Main Market and also on the New York Stock Exchange, and is a FTSE 100 constituent. Its portfolio spans Oral Health (Sensodyne, parodontax, Polident), vitamins, minerals and supplements (Centrum, Emergen-C), Pain Relief (Panadol, Advil, Voltaren), Respiratory (Otrivin, Theraflu) and Digestive health (ENO, TUMS). As of around 10 September 2026 the market capitalisation was roughly £29.6bn (about $40.5bn), on approximately 8.8bn shares, with the price near 336.2p against a 52-week range of 317.9p (3 June 2026) to 416.1p (18 February 2026).
Latest September 2026 developments
Haleon reported its 2026 half-year results on 30 July 2026. Revenue was £5,602m, up 2.2%, with organic revenue growth of 2.6% at constant currency (Q2 up 3.1%, and Oral Health up 6.2% in the second quarter). Adjusted operating profit rose 8.2% at constant currency to £1,364m, lifting the adjusted operating margin by 120 basis points to 24.3%. Reported operating profit fell 2.6% to £1,172m. Adjusted diluted EPS rose 12% to 10.3p, while reported diluted EPS was 8.5p. Free cash flow was £769m and net debt to adjusted EBITDA stood at 2.5x. The company had completed £457m of a £500m buyback allocation, and the interim dividend was raised 9% to 2.4p. Full-year 2026 guidance was left unchanged: organic revenue growth of 3–5% and high-single-digit adjusted operating profit growth at constant currency.
Major 2026 developments
On 8 January 2026 Haleon announced an evolution of its operating model, restructuring into six regional Operating Units and creating two new executive-committee roles, a Chief Growth Officer and a Chief Transformation Officer, with implementation targeted for mid-2026. The reorganisation is being led by chief executive Brian McNamara. Full-year 2025 preliminary results were published on 25 February 2026, and the buyback and dividend programmes continued through the period.
Products and commercial strategy
Haleon’s strength lies in a portfolio of category-leading brands with strong consumer recognition, supported by pricing power and the defensive repeat-purchase economics of self-care. Oral Health has been a particular bright spot, with Sensodyne and parodontax driving above-average growth in the second quarter. The operating-model evolution is intended to sharpen regional execution and support faster growth.
Financial position
The balance sheet shows net debt at 2.5x adjusted EBITDA, with healthy free cash flow of £769m in the half and a rising dividend alongside the buyback. The widening margin is a positive signal on execution, though the gap between organic growth and the top of the 3–5% target range bears watching.
What investors may be watching
Key items include whether organic growth accelerates in the second half towards the middle or upper end of the guided range, continued margin expansion, completion of the operating-model reorganisation by mid-2026, and the next major financial update at the full-year 2026 results due in February 2027, along with further progression of the buyback and dividend.
Key risks
Haleon’s organic growth has at times run below the 3–5% target, a recurring concern. Other company-specific risks include US consumer softness and retailer destocking, foreign-exchange translation given the international footprint, competition from private-label products, the execution risk attached to the restructuring, and the tail of legacy litigation inherited from its corporate history.
AstraZeneca PLC (LSE:AZN)
Company overview
AstraZeneca is a global biopharmaceutical company and the largest company in the FTSE 100 by market value, with additional listings on Nasdaq and in Stockholm. It operates across Oncology, Cardiovascular, Renal & Metabolism (CVRM), Respiratory & Immunology (R&I), Rare Disease, and Vaccines & Immune Therapies. As of around 10 September 2026 the market capitalisation was roughly £182.4bn (about $246.7bn), on approximately 1.55bn shares, with the price near 11,758p against a 52-week range of 10,784p to 15,730p, leaving it below its 12-month high.
Latest September 2026 developments
The standout recent event was a regulatory approval. On 4 September 2026 the US Food and Drug Administration granted Accelerated Approval to camizestrant, marketed as Etcamah, for HR-positive, HER2-negative locally advanced or metastatic breast cancer on detection of an ESR1 mutation during treatment with an aromatase inhibitor and a CDK4/6 inhibitor. This was the first FDA approval of a cancer therapy guided by a circulating-tumour-DNA resistance mutation before radiographic progression, based on the SERENA-6 trial, which showed median progression-free survival of 16.0 months versus 9.2 months. AstraZeneca had earlier disclosed that the FDA decision date had been extended to allow review of additional data.
Shortly before that, on 27 July 2026, the company reported its first-half and second-quarter results. Total revenue was $30.7bn, up 6% at constant currency, with product sales of $28.9bn, up 5%. Oncology was the engine, contributing $14.1bn, up 15% and representing 46% of the total. CVRM fell 12% to $6.1bn, R&I rose 9% to $4.8bn, and Rare Disease rose 11% to $4.9bn. The core operating margin was 34%, up one percentage point, and core EPS rose 11% at constant currency to $5.21, while reported EPS rose 3% to $3.60. Net debt was $26.9bn, up $3.5bn versus the end of 2025. The first interim dividend for 2026 was $1.06 per share, up 3 cents. Full-year 2026 guidance was for mid-to-high single-digit total revenue growth and low-double-digit core EPS growth. The top-selling products in the half were Farxiga at around $4.0bn, Tagrisso around $3.8bn, Imfinzi around $3.5bn, Ultomiris around $2.6bn, Calquence around $1.9bn, Enhertu around $1.7bn and Lynparza around $1.6bn.
Major 2026 developments
The full-year 2025 results, reported on 10 February 2026, showed total revenue of $58.7bn, up 8% at constant currency, and core EPS of $9.16, up 11% at constant currency. The company reaffirmed its ambition of around $80bn of revenue by 2030 and 20 new medicines by the end of the decade. The year brought a dense run of regulatory news. Camizestrant (Etcamah) also secured EU and Japan approvals in 2026. Datroway (datopotamab deruxtecan) received US approval and a positive EU CHMP opinion for certain triple-negative breast cancer patients ineligible for immunotherapy. Enhertu won multiple US approvals, including in adjuvant and neoadjuvant HER2-positive breast cancer, plus an EU approval in HER2-positive solid tumours. Baxdrostat, marketed as Baxfendy, was approved in the US for hypertension, with a Japan filing accepted. Truqap was approved in the US for PTEN-deficient metastatic prostate cancer, and Calquence received a Japan approval for fixed-duration chronic lymphocytic leukaemia. Imfinzi delivered six Phase III readouts, including positive results in VOLGA (bladder) and NILE (urothelial), though EMERALD-2 (hepatocellular carcinoma) was negative. Wainua’s Phase III CARDIO-TTRansform trial failed its primary endpoint in ATTR cardiomyopathy, and Fasenra secured regional approvals in hypereosinophilic syndrome. On business development, AstraZeneca struck deals with Dizal for Zegfrovy, an oral EGFR therapy ($600m upfront plus up to $900m in milestones), and with Sino Biopharm for TQC3721, a respiratory PDE3/4 programme ($200m upfront plus up to $1.9bn in milestones).
Products, pipeline and technology
The defining feature of AstraZeneca is the depth and breadth of its oncology franchise, now approaching half of total product sales, complemented by strong CVRM, R&I and Rare Disease portfolios. The camizestrant approval is scientifically notable as the first cancer therapy guided by a ctDNA resistance signal ahead of radiographic progression, pointing to where precision oncology is heading.
Financial position
Net debt rose to $26.9bn over the half, reflecting continued investment and business development, but the company’s scale, margin and cash generation remain substantial, and the dividend continues to rise.
What investors may be watching
Likely focal points include label expansion and confirmatory data for camizestrant, the launch of baxdrostat in hypertension, further Phase III oncology readouts, visible progress towards the $80bn-by-2030 ambition, and the full-year 2026 results in February 2027.
Key risks
AstraZeneca flags US drug-pricing policy and the Inflation Reduction Act, alongside the prospect of pharmaceutical tariffs. It carries significant China exposure with associated regulatory and investigation risk. A series of patent expiries looms over major products including Farxiga, Tagrisso, Imfinzi, Lynparza, Calquence and Soliris. Clinical-trial failure is an ever-present risk, as EMERALD-2 and CARDIO-TTRansform demonstrated in 2026, and foreign-exchange movements affect reported results.
Venture Life Group plc (LSE:VLG)
Company overview
Venture Life Group is a consumer self-care business trading on AIM and featuring in the FTSE AIM All-Share, with a portfolio spanning oral care, women’s intimate health, and ear and skin care. Its “Power Brands” include Lift (glucose), Balance Activ (women’s intimate health) and Earol (ear care), joined from 2026 by FemiClear and CUROXEN in the US. The company previously divested its contract development and manufacturing operation to focus on owned brands. As of around 10 September 2026 the market capitalisation was roughly £80.0m, on about 119.9m shares, with the price near 66.7p against a 52-week range of 52.0p to 71.75p.
Latest September 2026 developments
Venture Life changed its financial year-end to 31 May, from 31 December, creating a 17-month transition period ended 31 May 2026. A full-year trading update on 30 June 2026 reported 17-month revenue of £50.0m, up 30.9% versus the prior period, or up 16.0% on a pro-forma basis, with growth described as volume-led. Power Brands now account for more than 90% of sales. Adjusted EBITDA was expected to be in line with guidance, though the exact figure is not confirmed. Net cash was around £12.0m after the FemiClear/CUROXEN advance payment, and adjusted free cash flow was around £5.9m. The company is rolling out a digital-first, AI-enabled operating model on Microsoft Dynamics 365. A share buyback was launched on 20 August 2026, with transactions in its own shares continuing through August and September 2026.
Major 2026 developments
The defining corporate event of the year was the Acquisition of FemiClear and CUROXEN, announced on 3 June 2026, from OrganiCare for $28m — $23m upfront plus up to $5m deferred, contingent on 2026 trading — funded from existing cash. The acquired brands had combined net revenue of $12.1m, up 29.1%, and gross profit of around $7.5m in the 12 months to 31 March, with US retail distribution through Walmart, Walgreens, CVS and Target. The rationale is to expand Venture Life’s women’s intimate-health platform into a US feminine-treatment retail market estimated at around $0.7bn, with synergies expected from 2027.
Products and commercial strategy
Venture Life’s strategy is to build and acquire owned consumer self-care brands with strong margins and recurring demand, concentrating on its Power Brands, which now represent the overwhelming majority of sales. The FemiClear and CUROXEN deal both deepens the women’s intimate-health category and gives the group meaningful US retail distribution, though it also increases US-dollar exposure.
Financial position
The group reported net cash of around £12.0m after funding the acquisition from existing resources, alongside adjusted free cash flow of around £5.9m, a solid position for a company of this size. The year-end change means the next audited numbers will cover the unusual 17-month transition period.
What investors may be watching
Likely items include the full audited results for the 17-month period to 31 May 2026, expected around autumn 2026, the integration of FemiClear and CUROXEN and the 2027 synergies, the potential for further earnings-enhancing M&A, and the benefits from the AI-enabled operating model.
Key risks
As an AIM small-cap, Venture Life carries limited liquidity. Its growing US revenue brings US-dollar/sterling exposure. The integration of the newly acquired brands carries execution risk, and the business remains reliant on a small set of Power Brands, leaving it exposed to consumer demand and retailer dynamics.
Diaceutics PLC (LSE:DXRX)
Company overview
Diaceutics is a precision-medicine enablement business, providing diagnostic-testing data, analytics and engagement technology to pharmaceutical companies. It trades on AIM and features in the FTSE AIM All-Share. Its DXRX platform underpins two segments — Insight & Engagement Solutions and Scientific & Advisory Services — and its strategy is framed as “Precision for All”, built around an AI-enabled “PMx” platform serving global pharma customers. It has a December year-end. As of around 10 September 2026 the market capitalisation was roughly £124.8m, on about 84.9m shares, with the price near 156p against a 52-week range of 126.0p (28 July 2026) to 178.0p (7 May 2026).
Latest September 2026 developments
Diaceutics issued an H1 2026 trading update on 29 July 2026. Revenue was £17.5m, up 22% at constant currency from £14.6m in the first half of 2025. Annual Recurring Revenue reached £28.8m, up 75%, with net revenue retention of 146%. The company served 54 customers across 99 therapeutic brands, expected a gross margin of around 87%, and reported adjusted EBITDA of £1.1m. Cash was £8.1m and the company was debt-free. The order book stood at £43.7m, of which £15.7m was contracted for the second half of 2026, giving around 91% revenue visibility for the year. On 8 September 2026 Diaceutics issued a Notice of Results and Presentations, signalling that full H1 2026 interim results are imminent, and on 20 August 2026 it launched an NGS Concordance Study with PCC.
Major 2026 developments
Full-year 2025 results, published on 26 May 2026, showed revenue of £38.4m, up 20% (24% at constant currency), gross profit of £31.5m, and adjusted EBITDA of £7.6m, up 80%. The company returned to profit with a profit before tax of £0.3m, against a £1.9m loss previously, and ended the year with cash of £7.3m.
Products and technology
Diaceutics sells into the infrastructure of precision medicine, helping pharmaceutical companies understand and improve diagnostic testing so that the right patients are identified for targeted therapies. The shift towards recurring revenue — evident in the sharp rise in annual recurring revenue and the high net revenue retention — is central to the investment case, and the PCC NGS Concordance Study illustrates the kind of scientific Partnership that extends the platform.
Financial position
The company is debt-free with cash of £8.1m at the half year, and the high gross margin of around 87% underlines the software-and-data nature of the business. The large order book and roughly 91% revenue visibility for 2026 provide an unusually clear forward view for a company of this size.
What investors may be watching
The most immediate item is the full H1 2026 interim results, due in September 2026 following the 8 September Notice of Results. Beyond that, attention is likely to fall on continued growth in annual recurring revenue, new platform modules and partnerships such as the PCC NGS study, and the full-year 2026 outlook.
Key risks
Diaceutics is exposed to customer concentration and to the pharmaceutical R&D and commercial spending cycle. It depends on data partnerships and on data quality, and faces execution risk in its transition to recurring revenue. As an AIM company, its shares carry the liquidity characteristics of that market.
What Should Investors Watch During the Rest of September 2026?
A handful of near-term items are worth following through the remainder of the month, all drawn from the companies’ own disclosures.
The most imminent is Diaceutics. The company issued a Notice of Results and Presentations on 8 September 2026, which means its full H1 2026 interim results are due shortly. That report will Fill out the detail behind the strong trading update of 29 July, including the sharp rise in annual recurring revenue to £28.8m and the order book of £43.7m, and will give a fuller read on the 2026 outlook.
Second, the September 2026 FTSE index review takes effect on 21 September 2026. On the basis of the information available, there is no change to the index membership of any of these seven names at this review; Hikma’s relegation to the FTSE 250 took place back at the March 2026 review, and the three AIM companies sit in the FTSE AIM All-Share. Index reviews can nonetheless move trading volumes across the wider market, so the effective date is worth noting.
Third, AstraZeneca’s oncology regulatory flow continues. The camizestrant (Etcamah) accelerated approval on 4 September 2026 was the latest in a dense run of 2026 regulatory events, and the company has a deep pipeline of further Phase III readouts and filings. Any additional regulatory news would be consistent with the cadence seen through the year.
Beyond these, several companies have flagged updates that fall later in the calendar rather than within September — Venture Life’s audited 17-month results are expected around autumn 2026, and the full-year 2026 results for Hikma, ConvaTec, Haleon and AstraZeneca are due in February 2027. For the remainder of September specifically, the dossier supports only the three items above as verified near-term events; no other dated September milestones are confirmed for these names.
Conclusion
The seven companies surveyed here capture the range of what UK-listed healthcare offers in 2026. At one end sits AstraZeneca, a £180bn-plus biopharma whose oncology franchise and pipeline set the pace for the sector, and whose camizestrant approval in early September underlined how precision oncology is advancing. At the other end sit AIM minnows such as Shield Therapeutics, a single-product specialty pharma company inching towards profitability on a tight balance sheet, and Diaceutics, a data-and-analytics business growing recurring revenue at pace. In between are Haleon and Venture Life in consumer health, ConvaTec in chronic-care medtech, and Hikma in specialty generics.
A few themes tie them together. The United States is the pivotal market for nearly all of them, and US healthcare policy — on drug pricing, on reimbursement, and on the possibility of pharmaceutical tariffs — is the common external risk. ConvaTec’s InnovaMatrix impairment and Shield’s Medicaid-driven net-price erosion are concrete examples of how US reimbursement decisions feed straight through to results. The consumer-health names face a different but related pressure: the question of whether organic growth can reach the middle of their target ranges against soft US consumer demand. And the generics and medtech businesses contend with the structural price erosion and competition that define their markets.
The contrast in risk profiles is stark. The two mega-caps offer scale, Diversification and defensive cash generation, but carry their own issues — AstraZeneca’s looming patent cliffs and clinical-trial risk, Haleon’s sub-trend growth and restructuring execution. The AIM trio offer higher potential growth but with the liquidity constraints, single-product or single-customer dependencies, and balance-sheet sensitivities that come with their size.
For anyone following these names, the rationale for monitoring is the calendar of catalysts each has set out: interim results, regulatory decisions, integration milestones and full-year guidance. Diaceutics’ imminent interims, AstraZeneca’s continuing oncology flow, and the run of February 2027 results across the larger names are the signposts. None of this amounts to a view on whether any of these shares will outperform, and nothing here should be read as advice. The sector’s history is a reminder that clinical data, pricing policy and execution can all surprise in either direction, and that the gap between a company’s own guidance and the eventual outcome is where much of the risk — and the interest — lies. What these seven businesses share is that each has told the market clearly what to watch next, which makes them worth keeping on the radar through the autumn.






Please wait processing your request...